In case you didn’t know about Vivek Ramaswamy’s company Genevant….
‘Our unique capabilities…
Companies in the nucleic acid space typically work with only a singular modality, such as mRNA, siRNA or gene editors. Our multiple platforms provide the ability to exploit multiple constructs, and our technology is validated by the field-based licenses that we have granted to industry leaders.’
‘Genevant’s scientific leadership has pioneered Lipid Nanoparticle (LNP) nucleic acid delivery for 20+ years. With our proprietary advantages, LNPs can provide both optimal uptake into desired cells and efficient release, resulting in functional delivery of nucleic acid payloads to target tissues. Our LNP platform, the delivery technology behind the first and only siRNA-LNP product to achieve regulatory approval (Alnylam’s ONPATTROÂź), also enables a wide array of mRNA-based applications, including vaccines, therapeutic protein production, and gene editing.’
www.genevant.com/our-technology/
‘Our unique capabilities…
Companies in the nucleic acid space typically work with only a singular modality, such as mRNA, siRNA or gene editors. Our multiple platforms provide the ability to exploit multiple constructs, and our technology is validated by the field-based licenses that we have granted to industry leaders.’
‘Genevant’s scientific leadership has pioneered Lipid Nanoparticle (LNP) nucleic acid delivery for 20+ years. With our proprietary advantages, LNPs can provide both optimal uptake into desired cells and efficient release, resulting in functional delivery of nucleic acid payloads to target tissues. Our LNP platform, the delivery technology behind the first and only siRNA-LNP product to achieve regulatory approval (Alnylam’s ONPATTROÂź), also enables a wide array of mRNA-based applications, including vaccines, therapeutic protein production, and gene editing.’
www.genevant.com/our-technology/
In case you didn’t know about Vivek Ramaswamy’s company Genevant….
‘Our unique capabilities…
Companies in the nucleic acid space typically work with only a singular modality, such as mRNA, siRNA or gene editors. Our multiple platforms provide the ability to exploit multiple constructs, and our technology is validated by the field-based licenses that we have granted to industry leaders.’
‘Genevant’s scientific leadership has pioneered Lipid Nanoparticle (LNP) nucleic acid delivery for 20+ years. With our proprietary advantages, LNPs can provide both optimal uptake into desired cells and efficient release, resulting in functional delivery of nucleic acid payloads to target tissues. Our LNP platform, the delivery technology behind the first and only siRNA-LNP product to achieve regulatory approval (Alnylam’s ONPATTRO®), also enables a wide array of mRNA-based applications, including vaccines, therapeutic protein production, and gene editing.’
www.genevant.com/our-technology/
0 Kommentare
0 Anteile
2KB Ansichten
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek